Sciecure Pharma and HEC Pharm announce Strategic Partnership
Sciecure Pharma and HEC Pharm announce strategic partnership to launch and market pharmaceutical products in the UK and Germany. Sciecure Pharma and HEC Pharm will focus the UK and Germany market, to provide an effective and affordable treatment option to UK and Germany patients.
Sciecure, a mid-sized company with many of its resources located in China, was established in 2007 and is headquartered in Beijing, China. It currently employs over 400 employees with offices in China, the USA, Canada and the U.K. Sciecure has Research & Development, manufacturing facilities with oral solid dosage forms, small volume parenteral, lyophilized powder for injection, ampoules, large volume parenteral and Active Pharmaceutical Ingredient (API), as well as marketing networks throughout China.
About HEC Pharm
HEC Pharm is the subsidiary of HEC Group, a research-based and internationally oriented company. HEC Pharm was established in 2002. In 2006, HEC was granted a license from Roche to produce oseltamivir in China. They have set themselves the goal of improving the health of people by providing them with high-quality medicines.